Análisis Costo Efectividad del Stent Farmacológico V/S Stent no Farmacológico en Cardiopatía Isquémica en Chile Catherine De la Puente, MSc, Carlos Vallejos, MD, MSc, Mónica Velásquez, MSc, David Soto, MD, MSc, Juan Orellana, MSc Value in Health Regional Issues Volume 1, Issue 2, Pages 156-164 (December 2012) DOI: 10.1016/j.vhri.2012.09.008 Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Figura 1 modelo de Markow. Value in Health Regional Issues 2012 1, 156-164DOI: (10.1016/j.vhri.2012.09.008) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Figura 2 Diferencia de costos por diferencia de efectos con distintas tasas de descuento. Value in Health Regional Issues 2012 1, 156-164DOI: (10.1016/j.vhri.2012.09.008) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Figura 3 Curva de aceptabilidad para tasas de descuento de 0% ,3% y 6%. Value in Health Regional Issues 2012 1, 156-164DOI: (10.1016/j.vhri.2012.09.008) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions